Key Highlights
- After-hours trading saw Silo Pharma climb 47.55% to $0.52 on Monday
- European Patent Office delivered Rule 71(3) notification indicating planned patent approval for PTSD prevention treatment
- Patent protection encompasses methodologies utilizing serotonin 4 (5-HT4) receptor agonists for preventing stress-related fear and depression symptoms
- Columbia University holds the original patent, which Silo Pharma licenses exclusively, with anticipated coverage throughout key European territories
- Trading at approximately $4.98 million market capitalization, SILO remains significantly under its $1.18 annual peak
Monday brought significant momentum for Silo Pharma following the European Patent Office’s (EPO) issuance of a Rule 71(3) notification — a procedural indicator signaling planned patent approval — for an innovative preventative treatment approach to PTSD.
The submitted application bears the title “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” and centers on the serotonin 4 (5-HT4) receptor mechanism. This methodology emphasizes stopping stress-triggered fear responses and depressive symptoms before they manifest, diverging from conventional post-symptom treatment strategies.
Columbia University serves as the original patent holder, with Silo Pharma maintaining exclusive licensing rights. The company is currently assessing both Unitary Patent safeguards and individual country validations throughout Europe to maximize territorial reach.
CEO Eric Weisblum characterized the development as a “significant value-creating achievement” that bolsters the organization’s worldwide intellectual property framework.
Patent Scope and Applications
The approved claims detail specific methodologies for preventing stress-triggered fear responses, depression-like behaviors, and associated affective conditions through designated 5-HT4 receptor agonists.
This represents a departure from conventional PTSD interventions that address post-emergence symptoms. Silo’s strategy concentrates on establishing stress resistance proactively.
The patent provides direct foundation for SPC-15, Silo’s primary PTSD development program. The company’s additional pipeline encompasses SP-26 targeting fibromyalgia and chronic pain conditions, alongside early-stage candidates addressing Alzheimer’s disease.
Stock Performance Analysis
SILO concluded regular Monday trading at $0.36 before jumping to $0.52 during extended hours — representing a 47.55% increase.
The annual trading range provides broader context: shares reached $1.18 at the peak and bottomed at $0.22 over twelve months. These fluctuations are substantial for an entity valued just below $5 million in market capitalization.
Benzinga’s equity assessments indicated SILO demonstrated unfavorable price momentum across multiple timeframes prior to Monday’s announcement.
The extended-session rally positions the stock above the $0.50 threshold for the first time in recent sessions, although it continues trading well beneath its annual high.
Once the EPO formally finalizes the grant, Silo’s PTSD therapeutic approach is projected to receive protection throughout principal European jurisdictions.
